EVH

Company Overview — What Does Evolent Health, Inc. Do?

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia. Evolent Health, Inc. (EVH) is classified as a micro-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO Seth B. Blackley and employs approximately 5,100 people, headquartered in ARLINGTON, Virginia. With a market capitalization of $248M, EVH is one of the notable companies in the Industrials sector.

Evolent Health, Inc. (EVH) Stock Rating — Avoid (April 2026)

As of April 2026, Evolent Health, Inc. receives a Avoid rating with a composite score of 27.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.EVH ranks #4,210 out of 4,446 stocks in our coverage universe. Within the Industrials sector, Evolent Health, Inc. ranks #722 of 752 stocks, placing it in the lower half of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EVH Stock Price and 52-Week Range

Evolent Health, Inc. (EVH) currently trades at $2.34. The stock lost $0.10 (4.0%) in the most recent trading session. The 52-week high for EVH is $12.06, which means the stock is currently trading -80.6% from its annual peak. The 52-week low is $2.50, putting the stock -6.3% above its annual trough. Recent trading volume was 3.6M shares, reflecting moderate market activity.

Is EVH Overvalued or Undervalued? — Valuation Analysis

Evolent Health, Inc. (EVH) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.68x, versus the sector average of 2.23x. The price-to-sales ratio is 0.14x, compared to 0.50x for the average Industrials stock. On an enterprise value basis, EVH trades at 3.44x EV/EBITDA, versus 5.70x for the sector.

At current multiples, Evolent Health, Inc. trades at a premium to most Industrials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Evolent Health, Inc. Profitability — ROE, Margins, and Quality Score

Evolent Health, Inc. (EVH) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -39.9%, compared to the Industrials sector average of 8.9%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.7% versus the sector average of 3.3%.

On a margin basis, Evolent Health, Inc. reports gross margins of 19.4%, compared to 35.8% for the sector. The operating margin is -0.8% (sector: 6.2%). Net profit margin stands at -8.6%, versus 3.9% for the average Industrials stock. Revenue growth is running at -25.9% on a trailing basis, compared to 6.4% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

EVH Debt, Balance Sheet, and Financial Health

Evolent Health, Inc. has a debt-to-equity ratio of 357.0%, compared to the Industrials sector average of 70.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.31x, suggesting adequate working capital coverage. Total debt on the balance sheet is $1.06B. Cash and equivalents stand at $117M.

EVH has a beta of 0.69, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Evolent Health, Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Evolent Health, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Evolent Health, Inc. reported revenue of $2.03B and earnings per share (EPS) of $-5.07. Net income for the quarter was $-166M. Gross margin was 19.4%. Operating income came in at $-18M.

In FY 2025, Evolent Health, Inc. reported revenue of $1.88B and earnings per share (EPS) of $-5.07. Net income for the quarter was $-579M. Gross margin was 21.3%. Revenue grew -26.6% year-over-year compared to FY 2024. Operating income came in at $-410M.

In Q3 2025, Evolent Health, Inc. reported revenue of $480M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-27M. Gross margin was 20.8%. Revenue grew -22.8% year-over-year compared to Q3 2024. Operating income came in at $886,000.

In Q2 2025, Evolent Health, Inc. reported revenue of $444M and earnings per share (EPS) of $-0.44. Net income for the quarter was $-51M. Gross margin was 22.6%. Revenue grew -31.3% year-over-year compared to Q2 2024. Operating income came in at $-1M.

Over the past 8 quarters, Evolent Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $647M to $2.03B. Investors analyzing EVH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

EVH Dividend Yield and Income Analysis

Evolent Health, Inc. (EVH) does not currently pay a dividend. This is common among smaller companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.

EVH Momentum and Technical Analysis Profile

Evolent Health, Inc. (EVH) has a momentum factor score of 10/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

EVH vs Competitors — Industrials Sector Ranking and Peer Comparison

Within the Industrials sector, Evolent Health, Inc. (EVH) ranks #722 out of 752 stocks based on the Blank Capital composite score. This places EVH in the lower half of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.

Comparing EVH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EVH vs S&P 500 (SPY) comparison to assess how Evolent Health, Inc. stacks up against the broader market across all factor dimensions.

EVH Next Earnings Date

No upcoming earnings date has been announced for Evolent Health, Inc. (EVH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EVH? — Investment Thesis Summary

The quantitative profile for Evolent Health, Inc. suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 10/100, a headwind for near-term performance.

In summary, Evolent Health, Inc. (EVH) earns a Avoid rating with a composite score of 27.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EVH stock.

Related Resources for EVH Investors

Explore more research and tools: EVH vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EVH head-to-head with peers: EVH vs SOBO, EVH vs TEN, EVH vs GLDD.